800 participants
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-08-27
- Start Date:
- 2023-06-13
- Completion:
- 2027-01-21
Conditions
- Relapsing Multiple Sclerosis
Interventions
- BIOLOGICAL
- DRUG
No Results Yet